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Abstract
We aimed to identify metabolic disorders associated with insulin resistance (IR) in 
Congolese women affected by polycystic ovary syndrome (PCOS). Fifty‐four PCOS 
women and 40 controls from three hospitals of Kinshasa were enrolled to our case‐con‐
trol study. Blood samples were collected, and concentrations of high‐density lipoprotein 
(HDL) and low‐density lipoprotein (LDL) cholesterol, triglycerides (TG), fasting insulin, 
and glucose levels were measured. IR under basal conditions was evaluated with homeo‐
stasis model assessment (HOMA‐IR). Dyslipidemia was observed in 37.5 controls and 
55.6% PCOS women (p < 0.05). The two main lipoproteins concerned were HDL and LDL; 
nevertheless, the difference in LDL levels between PCOS and controls was not significant. 
Higher TG (>150 mg/dl) was not found in the two groups, whereas TG levels in PCOS 
patients were significantly higher than in controls (p < 0.05). Impaired glucose tolerance 
(IGT) and metabolic syndrome were observed, respectively, in 1.9% of PCOS patients. 
Insulin resistance is associated with metabolic disorders in Congolese woman with PCOS. 
Dyslipidemia (55.6%), mainly due to low HDL levels, is the most common metabolic dis‐
order. Impaired glucose tolerance and metabolic syndrome represent a small proportion.
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1. Introduction
Polycystic ovary syndrome (PCOS) characterized by androgen excess with or without clinical 
evidence of hyperandrogenism is one of the most common endocrine dysfunctions that affects 
5–10% of women of reproductive age [1, 2]. Literature data revealed that PCOS is associated 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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with several metabolic complications, including insulin resistance (IR) with compensatory 
hyperinsulinemia, impaired glucose tolerance, dyslipidemia, and metabolic syndrome (MS) 
[2–4].
PCOS women with dyslipidemia show lower HDL and higher TG, without change in LDL 
[5, 6].
Apridonidze et al. [7] observed that 68% of women had low HDL and 35% higher triglycer‐
ides. Another American multicentric study showed lower HDL in 66% of cases and higher TG 
in 32% of cases [8].
Metabolic syndrome is found in the third part of PCOS women [6, 8–11]. It appears in women 
with obesity or overweight, suggesting a “knock effect” of the gain of weight, probably in 
genetically predetermined women [5]. It has been found, respectively, in 43% of PCOS women 
by Apridonidze et al. [7] and 33.4% by Ehrmann et al. [8].
Likewise, race and age affect the prevalence of IR and metabolic disorders. Therefore, 
measures used to estimate these features in PCOS patients might take into account these 
factors.
Currently, few data are available on the prevalence and metabolic disorders of PCOS in 
African women. Therefore, the present study aimed to determine the frequency and metabolic 
features associated with IR in Congolese women affected by PCOS using a case‐control study.
2. Patients and methods
The present study was carried out from February 2006 to February 2007 in three hospitals 
of Kinshasa. Fifty‐four women with PCOS were recruited while a group of 40 healthy, age 
matched female subjects were used as controls. Women were all black, African, and from a 
Congolese ethnic group. Presence of PCOS was defined according to the Rotterdam 2003 con‐
sensus [1] by the presence of at least two of the following three features: (1) clinical and/or bio‐
chemical signs of hyperandrogenism; (2) oligomenorrhea, that is, menstrual cycles > 45 days 
or less eight cycles/year and/or anovulation; and (3) presence of polycystic ovaries. Clinical 
hyperandrogenism was defined by the Ferriman‐Gallwey score (F‐G score) as > 8. None of 
these PCOS patients had used hormonal preparation for at least 2 months preceding the study. 
Control women came from the same ethnic group; they were non‐hirsute, without personal or 
family history of hirsutism and/or endocrine disorders, and free of any treatment. They had 
regular menstrual cycles, and none of them satisfied any of the PCOS criteria of the Rotterdam 
2003 consensus.
PCOS and controls were excluded if they were prepubertal, premenopausal, or pregnant.
All women were subjected to a physical examination including evaluation of blood pressure, 
weight, abdominal, and hip circumference. Parametric measures included evaluation of body 
mass index (BMI) and waist‐to‐hip ratio (WHR). The waist circumference (WC) was defined 
as the smallest measurement between the iliac crest and lateral costal margin and the hip cir‐
cumference, as the largest measurement over the buttocks. BMI was defined as body weight in 
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kilograms divided by body height in meters squared (kg/m2). Overweight was defined as BMI 
≥ 25 kg/m2, and obesity was defined as BMI ≥ 30 kg/m2, while WHR > 0.85 indicated visceral 
type of obesity.
2.1. Biochemistry
Capillary glucose was measured using a glucometer (Glucocard, Menarini, Italy). Serum 
insulin was performed by ELISA using the Mercodia Insulin Elisa kit. We also measured in 
serum HDL and LDL cholesterol and triglycerides by colometric enzymatic method.
Dyslipidemia was defined by one or more abnormal lipidic fractions using as normal values 
for LDL ≤ 160, HDL ≥ 50, and triglycerides < 150 mg/dl.
Impaired glucose tolerance (IGT) was defined as fasting hyperglycemia between 110 and 
126 mg/dl.
Metabolic syndrome was defined according to Rotterdam 2003 consensus [1] by at least three 
of the following criteria:
• Abdominal circumference > 88 cm
• Triglycerides ≥ 150 mg/dl
• HDL cholesterol < 50 mg/dl
• Blood pressure ≥ 130/≥ 85 mmHg
• Fasting glucose > 110–126 and/or 2‐h of glucose > 140–199 mg/dl
2.2. Statistical analysis
Data were analyzed with commercial software (SPSS version 13.0 for Windows). The Chi‐
square test, Fisher's exact test, and t‐test were used to make comparison of quantitative vari‐
ables and qualitative variables between study groups and sub‐groups, according to each case. 
A p value < 0.05 was considered statistically significant.
3. Results
Table 1 shows the clinical features of PCOS patients and controls. The mean age and BMI 
were similar in both groups. There was a significant difference for menarche age between the 
two groups (p < 0.05) as well as for the Ferriman & Gallwey (F‐G) score (p < 0.001), HDL, and 
TG (p <0.05).
As shown in Table 2, dyslipidemia was found among 37.5% of controls and 55.6% of PCOS 
patients. HDL and LDL were the two lipidic fractions concerned. Lower HDL was the main 
abnormality observed (p < 0.001).
Higher TG (≥ 150 mg/dl) was not found although there was a significant difference between 
PCOS group and controls (Table 1).
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Parameters PCOS (n = 54) Controls (n = 40)
HDL‐c (mg/dl)
<50 27 (50%) 14 (35%)
≥50 27 (50%) 25 (65%)
LDL‐c (mg/dl)
<160 49 (90.7%) 39 (97.5%)
≥160 5 (9.3%) 1 (2.5%)
TG (mg/dl)
<150 54 (100%) 40 (100%)
≥150 0 (0%) 0 (0%)
Dyslipidemia
Present 30 (55.6%) 15 (37.5%)
Absent 24 (44.4%) 25 (62.5%)
Table 2. Prevalence of dyslipidemia.
Parameters PCOS (n = 54) Controls (n = 40) P
Age 24.54 ± 5.2 23.98 ± 6.3 NS
Menarche age 13.77 ± 1.6 12.62 ± 1.6 <0.05
Ferriman‐Gallwey Score 9.46 ± 6.1 3.38 ± 2.4 <0.001
Systolic blood pressure 
(mmHg)
110.57 ± 13.36 107.25 ± 9.3 NS
Diastolic blood pressure 
(mmHg)
71.70 ± 12.36 70.50 ± 9.0 NS
BMI 22.0 ± 4.39 22.0 ± 3.32 NS
WC (cm) 76.85 ± 10.9 75.82 ± 8.3 NS
WHR 0.80 ± 0.06 0.77 ± 0.05 NS
Glucose (mg/dl) 78.83 ± 12.7 76.42 ± 10.5 NS
Insulin (µU/L) 13.06 ± 9.1 5.83 ± 3.6 <0.001
HOMA‐IR (mol × µU/l2) 2.62 ± 2.1 1.08 ± 0.67 <0.001
HDL‐cholesterol (mg/dl) 49.07 ± 13.72 57.65 ± 16.55 <0.05
LDL‐cholesterol (mg/dl) 106.8 ± 31.6 111.10 ± 24.5 NS
Triglycerides (mg/dl) 57.12 ± 21.6 48.52 ± 12.87 <0.05
Table 1. Clinical and biochemical features of the study subjects.
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Among PCOS women, dyslipidemia varied significantly by waist‐to‐hip ratio, HDL, and TG.
PCOS patients identified as having dyslipidemia were compared with those without dys‐
lipidemia. Overall, PCOS patients with dyslipidemia had the same age and LDL level but 
lower HDL and higher TG level. In addition, they had greater android body fat distribution. 
There was no difference in the HOMA‐IR index, although patients with dyslipidemia showed 
higher level of this parameter (Table 3).
Impaired glucose tolerance as well as metabolic syndrome was observed in only one PCOS 
women.
4. Discussion
In our knowledge, this is the first study that describes lipid and lipoprotein profile and meta‐
bolic disorders associated to IR in Congolese women with PCOS.
We determined lipids and lipoprotein levels which were in the normal range. Our results 
are in accordance with previous African studies which had found lower levels of lipid and 
lipoprotein in African people compared to values reported in Caucasians [12–16, 22]. This 
difference could be explained by the low‐fat and high‐carbohydrate African diet. Indeed, 
nutritional transition is in process in Kinshasa. Although few people have modified their diet, 
eating more and more refined sugar and animal fat and less vegetable, the diet in people from 
Kinshasa remains poor in fat and wealthy in carbohydrates.
We observed in our study among PCOS women lower HDL and higher TG without change in 
LDL and this is consistent with other previous reports [7, 8, 17]. This inverse relation between 
HDL and TG is commonly found in insulin resistance and hyperinsulinemia.
We failed to observe a significant association between metabolic syndrome and biological 
insulin resistance as reported by several authors [5, 7, 8, 18, 19], possibly owing to the TG 
level ≥ 150 mg/dl in the metabolic syndrome's definition that we used. In addition, the small 
number of obeses in our PCOS group could also explain this observation. Previous studies 
Parameters PCOS with dyslipidemia 
(n = 30)
PCOS without dyslipidemia (n = 24) P
WHR 0.81 ± 0.05 0.78 ± 0.06 <0.05
HDL‐c 40.70 ± 10.09 59.53 ± 9.98 <0.001
LDL‐c 111.63 ± 34.5 100.76 ± 27.2 NS
TG 63.6 ± 23.4 49.02 ± 16.1 <0.05
HOMA‐IR 2.8 ± 2.3 2.4 ± 1.7 NS
Table 3. Variations of dyslipidemia among PCOS subjects.
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have reported greater proportion of obesity and overweight subjects. Indeed, the prevalence 
of metabolic syndrome increases with the rise of BMI [9, 10, 18, 20]. Overall, 30–50% of obesity 
or overweight can be found in women with PCOS. In the USA, more than 30% of adults are 
obese [5, 21]. In our study, only 3.7% of PCOS women were obese.
We observed the so‐called TG paradox that has been described in Sub‐Saharan African popu‐
lations: normal triglycerides levels in the presence of IR [22].
The generally accepted cut‐off point of TG level (≥ 150 mg/dl) could underestimate dys‐
lipidemia and metabolic syndrome in African people due to lower lipid and lipoprotein 
levels reported in several African studies [12–16, 22]. It is, therefore, important to describe 
African lipid and lipoprotein profile and to propose another definition of metabolic syn‐
drome, either in PCOS and in other patients. These findings may allow to discover existing 
metabolic syndrome in most of the PCOS patients from our study that could not be deter‐
mined using international lipid and lipoprotein levels and the Rotterdam 2003 metabolic 
syndrome definition.
There were inherent limitations associated with this study: one of them was the limited num‐
ber of patients. However, given the paucity of data available on PCOS in African women, our 
data, even though collected among a limited number of patients, confirm the need for further 
knowledge in endocrine and metabolic diseases in developing countries.
5. Conclusion
It is concluded that insulin resistance is associated with metabolic disorders in Congolese woman 
with PCOS. Dyslipidemia (55.6%), mainly due to low HDL levels, is the most common metabolic 
disorder. Impaired glucose tolerance and metabolic syndrome represent a small proportion.
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